Abstract
Background: Cutaneous adverse events can have an important negative influence on quality of life and compliance in affected patients. Palmoplantar erythrodysesthesia (PPE; hand-foot syndrome) is a cutaneous toxicity associated with chemotherapeutic treatment, which necessitates treatment interruption or dose reduction in severe cases. This case report of pegylated liposomal doxorubicin-induced PPE shows the influence of mechanical stress on the development of skin lesions in various locations and the importance of patient education and compliance. Case Report: We present the case of a 43-year-old female patient diagnosed with ovarian cancer and having undergone surgical and chemotherapeutic treatment. The development of extensive grade 3 PPE affecting numerous areas of the body particularly exposed to mechanical pressure necessitated dermatological treatment. The combination of local application of an antioxidant-containing ointment and the patient's compliance made it possible to continue chemotherapy without interruption or dose reduction. Conclusion: The development of PPE often limits the use of chemotherapeutic agents, and this case report can provide a possible therapeutic and preventive strategy for affected patients.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Webster-Gandy JD, How C, Harrold K: Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-246.
[PubMed]
2.
Farr KP, Safwat A: Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011;4:229-235.
[PubMed]
3.
Lademann J, Rowert-Huber HJ, Haas N, Kluschke F, Patzelt A, Zastrow L, Lange-Asschenfeldt B, Jung S, Sterry W, Sehouli J: Palmoplantar erythrodysesthesia-like skin symptoms in patients under various chemotherapeutics: preventive and therapeutic options. Skin Pharmacol Physiol 2014;27:228-232.
[PubMed]
4.
National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. NIH publication no. 09-7473, 2009.
5.
Yokomichi N, Nagasawa T, Coler-Reilly A, Suzuki H, Kubota Y, Yoshioka R, Tozawa A, Suzuki N, Yamaguchi Y: Pathogenesis of hand-foot syndrome induced by peg-modified liposomal doxorubicin. Hum Cell 2013;26:8-18.
[PubMed]
6.
Green AE, Rose PG: Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine 2006;1:229-239.
[PubMed]
7.
Ko EM, Lippmann Q, Caron WP, Zamboni W, Gehrig PA: Clinical risk factors of pegylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecol Oncol 2013;131:683-688.
[PubMed]
8.
Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, Gutzmer R: The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 2010;8:652-661.
[PubMed]
9.
Hueso L, Sanmartin O, Nagore E, Botella-Estrada R, Requena C, Llombart B, Serra-Guillen C, Alfaro-Rubio A, Guillen C: (Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases). Actas Dermosifiliogr 2008;99:281-290.
[PubMed]
10.
Von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J, Hauschild A: Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008;44:781-790.
[PubMed]
11.
Von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, Waggoner S: A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010;116:4735-4743.
[PubMed]
12.
Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303-306.
[PubMed]
13.
Son H-S, Lee WY, Lee W-S, Yun SH, Chun H-K: Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J 2009;50:796.
[PubMed]
14.
Lipworth AD, Robert C, Zhu AX: Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-271.
[PubMed]
15.
Beard JS, Smith KJ, Skelton HG: Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. J Am Acad Dermatol 1993;29:325-330.
[PubMed]
16.
Nagore E, Insa A, Sanmartin O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1:225-234.
[PubMed]
17.
Schmook T, Jacobi U, Lademann J, Worm M, Stockfleth E: Detection of doxorubicin in the horny layer in a patient suffering from palmar-plantar erythrodysaesthesia. Dermatology 2005;210:237-238.
[PubMed]
18.
Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W, Lademann J: Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1211.
[PubMed]
19.
Martschick A, Sehouli J, Patzelt A, Richter H, Jacobi U, Oskay-Ozcelik G, Sterry W, Lademann J: The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 2009;29:2307-2313.
[PubMed]
20.
Meta-analysis group in cancer, Lévy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, Thirion P: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-3541.
[PubMed]
21.
Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A, Jung S, Chekerov R, Darvin ME, Haas N, Sterry W, Zastrow L, Sehouli J: Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. Skin Pharmacol Physiol 2014;27:66-70.
[PubMed]
22.
Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-1047.
[PubMed]
23.
Kara IG, Sahin B, Erkisi P: Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414-424.
[PubMed]
24.
Kluschke F, Martschick A, Darvin ME, Zastrow L, Chekerov R, Lademann J, Sehouli J: Application of an ointment with high radical protection factor as a prevention strategy against PPE. J Clin Oncol 2012;30(suppl):abstr 5064.
25.
Hofheinz RD, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I, Hochhaus A, Stintzing S: Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Brit J Cancer 2012;107:1678-1683.
[PubMed]
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
